Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Cash from Investing Activities (2016 - 2025)

Historic Cash from Investing Activities for Gyre Therapeutics (GYRE) over the last 17 years, with Q3 2025 value amounting to -$1.2 million.

  • Gyre Therapeutics' Cash from Investing Activities rose 4775.87% to -$1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$4.3 million, marking a year-over-year increase of 7384.68%. This contributed to the annual value of -$19.9 million for FY2024, which is 62.75% down from last year.
  • Gyre Therapeutics' Cash from Investing Activities amounted to -$1.2 million in Q3 2025, which was up 4775.87% from -$3.0 million recorded in Q2 2025.
  • Gyre Therapeutics' 5-year Cash from Investing Activities high stood at $52.9 million for Q2 2022, and its period low was -$69.2 million during Q4 2022.
  • Moreover, its 5-year median value for Cash from Investing Activities was -$1.6 million (2024), whereas its average is -$421722.2.
  • Examining YoY changes over the last 5 years, Gyre Therapeutics' Cash from Investing Activities showed a top increase of 39393.68% in 2022 and a maximum decrease of 251413.12% in 2022.
  • Over the past 5 years, Gyre Therapeutics' Cash from Investing Activities (Quarter) stood at $2.9 million in 2021, then plummeted by 2514.13% to -$69.2 million in 2022, then skyrocketed by 101.94% to $1.3 million in 2023, then crashed by 249.66% to -$2.0 million in 2024, then skyrocketed by 37.77% to -$1.2 million in 2025.
  • Its Cash from Investing Activities stands at -$1.2 million for Q3 2025, versus -$3.0 million for Q2 2025 and $2.0 million for Q1 2025.